Neulasta and Ejection fraction - a phase IV clinical study of FDA data

Summary:

Ejection fraction is reported as a side effect among people who take Neulasta (pegfilgrastim), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Decadron, and have Adenocarcinoma.

The phase IV clinical study analyzes which people have Ejection fraction when taking Neulasta. It is created by eHealthMe based on reports of 92,148 people who have side effects when taking Neulasta from the FDA, and is updated regularly.

What is Neulasta?

Neulasta has active ingredients of pegfilgrastim. It is often used in agranulocytosis. eHealthMe is studying from 92,286 Neulasta users. Check the latest studies of Neulasta.

What is Ejection fraction?

Ejection fraction (the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat) is found to be associated with 376 drugs and 321 conditions by eHealthMe. Check the latest studies of Ejection fraction.

On Jul, 06, 2026

92,148 people reported to have side effects when taking Neulasta.
Among them, 11 people (0.01%) have Ejection fraction.

$Could Neulasta cause Ejection fraction?$

Among these 11 people:

How long have people been on Neulasta when they have Ejection fraction? *

What is the gender of people who have Ejection fraction when taking Neulasta? *

female: 36.36 %
male: 63.64 %

What is the age of people who have Ejection fraction when taking Neulasta? *

What are other drugs people take besides Neulasta? *

What are other side effects people have besides Ejection fraction? *

Stress And Anxiety: 9 people, 81.82%
Swallowing Difficulty: 8 people, 72.73%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 7 people, 63.64%
Gastritis (inflammation of stomach): 7 people, 63.64%
Fall: 7 people, 63.64%
Osteomyelitis (infection of bone): 7 people, 63.64%
Fever: 7 people, 63.64%
Gallbladder Disorder: 7 people, 63.64%
Neuritis (inflammation of nerve): 7 people, 63.64%
Aortic Arteriosclerosis (hardening of the aortic arteries): 7 people, 63.64%

What are the existing conditions these people have? *

Anaemia (lack of blood): 1 person, 9.09%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Neulasta and have Ejection fraction?

- Check whether Ejection fraction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Neulasta:

Neulasta (92,286 reports)

Browse all side effects of Neulasta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ejection fraction:

Ejection fraction (376 drugs)

Browse all the conditions that are associated with Ejection fraction:

Ejection fraction (321 conditions)

Related publications that referenced our studies

Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .
Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pegfilgrastim (the active ingredients of Neulasta) and Neulasta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.